Disease-modifying therapy, in multiple sclerosis

Goodin DS, Frohman EM, Garmany GR et al. Disease modifying therapies in multiple sclerosis report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002 58 169-178. 

Frohman E, Phillips T, Kokel K, et al. Disease-modifying therapy in multiple sclerosis Strategies for optimizing management. Neurology 2002 8 227-236. 

Despite encouraging results from well-conducted clinical trials, several relevant issues remain. The most important question in the use of the ABC-R drugs is when to begin therapy. The Medical Advisory Board of the National Multiple Sclerosis Society has adopted recommendations regarding the use of the current MS disease-modifying agents, and these are summarized in Table 53-3. ... 

---